OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Disis on the Investigation of the CAR T-Cell Therapy PRGN-3005 in Ovarian Cancer

June 12th 2023

Mary “Nora” Disis, MD, discusses the results of a phase 1/1b study of PRGN-3005 autologous UltraCAR T cells in patients with advanced stage platinum-resistant ovarian cancer.

Dr Choueiri on the Results of the CONTACT-03 Trial in Metastatic RCC

June 12th 2023

Toni Choueiri, MD, discusses the results of the phase 3 CONTACT-03 trial (NCT04338269) of atezolizumab and cabozantinib in patients with metastatic renal cell carcinoma.

Dr Minchom on the Safety of Subcutaneous Amivantamab in Advanced Solid Tumors

June 12th 2023

Anna R. Minchom MD, BCh, MB, MRCP, discusses the safety and recommended phase 2 doses of subcutaneous amivantamab-vmjw for patients with advanced solid tumors in the phase 1b PALOMA trial.

Dr Dholaria on Updated Efficacy Data From the TRIMM-2 Trial of Talquetamab and Daratumumab in R/R Multiple Myeloma

June 12th 2023

Bhagirathbhai Dholaria, MBBS, discusses additional 10-month follow-up data from the phase 1 TRIMM-2 trial of subcutaneous talquetamab and daratumumab in relapsed/refractory multiple myeloma.

Dr Levis on Maintenance Gilteritinib After ASCT in FLT3-ITD+ AML

June 11th 2023

Mark J. Levis, MD, PhD, discusses data from the phase 3 BMT CTN 1506/MORPHO trial of gilteritinib as maintenance therapy following allogeneic stem cell transplant in patients With FLT3-ITD–positive acute myeloid leukemia.

Dr Munshi on the Final Results of the CARTITUDE-1 Trial of Cilta-Cel in R/R Myeloma

June 11th 2023

Nikhil C. Munshi, MD, discusses the efficacy data from the final analysis of the phase 1b/2 CARTITUDE-1 trial of ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma.

Dr Shaw on the Heterogeneity Between Paired Primary and Metastatic Solid Tumors

June 10th 2023

Timothy I Shaw, PhD, discusses the genetic heterogeneity between paired primary and metastatic solid tumors, as well as the implications for neoantigen-based personalized vaccines in cancer care.

Dr Mohty on Extended Follow-up Data from MagnetisMM-3 With Elranatamab in R/R Myeloma

June 10th 2023

Mohamad Mohty, MD, PhD, discusses extended follow-up from cohort A of the phase 2 MagnetisMM-3 trial of elranatamab in patients with relapsed/refractory multiple myeloma.

Dr Al-Ali on the Safety and Efficacy of BMS-986158 Plus Ruxolitinib or Fedratinib in Myelofibrosis

June 10th 2023

Haifa Kathrin Al-Ali, MD, discusses the safety and efficacy findings from the dose-escalation portion of the phase 1/2 CA011-023 trial of BMS-986158 in combination with ruxolitinib or fedratinib in patients with intermediate- or high-risk myelofibrosis.

Dr Partridge on Breast Cancer Recurrence in Young Breast Cancer Survivors

June 9th 2023

Ann H. Partridge, MD, MPH, discusses the incidence of second primary breast cancer in young patients with a history of breast cancer.

Dr Van Tine on Investigating Cabozantinib With PD-1 and CTLA-4 Inhibition in Sarcoma

June 9th 2023

Brian A. Van Tine, MD, PhD, discusses the rationale for launching a randomized phase 2 trial investigating cabozantinib combined with nivolumab and ipilimumab vs cabozantinib alone in metastatic soft tissue sarcoma and discusses key findings from the trial.

Dr Pant on the Investigation of Zanidatamab in Biliary Tract Cancer

June 9th 2023

Shubham Pant, MD, MBBS, discusses the rationale for the phase 2b HERIZON-BTC-01 trial and shares the results with zanidatamab in previously treated HER2-amplified biliary tract cancer.

Dr Schlechter on TAC01-HER2 Therapy in HER2+ Solid Tumors

June 9th 2023

Benjamin L. Schlechter, MD, discusses the future implications of TAC01-HER2 therapy in patients with HER2-positive solid tumors.

Dr Gill on the Evaluation of Oral Arsenic Trioxide Plus ATRA/Ascorbic Acid in APL

June 9th 2023

Harry Gill, MD, FRCP, FRCPath, discusses the investigation of an all-oral combination of arsenic trioxide, all trans retinoic acid, and ascorbic acid in patients with newly diagnosed acute promyelocytic leukemia.

Dr Jabbour on the Efficacy of Ponatinib in Newly Diagnosed Ph+ ALL

June 9th 2023

Elias Jabbour, MD, discusses efficacy data from the phase 3 PhALLCON trial of ponatinib plus reduced-intensity chemotherapy vs imatinib plus reduced-intensity chemotherapy in newly diagnosed patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.

Dr Kasper on the Evaluation of Nirogacestat in Desmoid Tumors in the DeFi Trial

June 9th 2023

Bernd Kasper, MD, PhD, professor, Universitätsmedizin Mannheim, Mannheim, discusses the effect of nirogacestat on tumor volume and T2 hyperintensity in patients with desmoid tumors.

Dr Waks on Survival Outcomes With Chemotherapy in Small Node-Negative HER2+ Breast Cancer

June 9th 2023

Adrienne G. Waks, MD, discusses breast cancer survival in patients with small node-negative HER2-positive breast cancer according to the treatment modality received.

Dr Johnson on Domvanalimab, Zimberelimab, and Etrumadenant in NSCLC

June 8th 2023

Melissa L. Johnson, MD, discusses findings from the phase 2 ARC-7 trial in patients with previously untreated metastatic, PD-L1–high non–small cell lung cancer.

Dr Luo on the Potential Use of KB-0742 In MYC-Amplified Tumors

June 8th 2023

Jia Luo, MD, discusses the potential use of KB-0742 to target specific MYC-driven tumor types, as well as challenges in the detection of MYC amplification or overexpression in clinical practice.

Dr Johnson on BL-B01D1 in Locally Advanced or Metastatic Solid Tumors

June 8th 2023

Melissa L. Johnson, MD, discusses findings from the phase 1 BL-B01D1-101 trial investigating the efficacy and safety of the EGFR- and HER3-directed antibody-drug conjugate BL-B01D1 in patients with locally advanced or metastatic solid tumors, including non–small cell lung cancer.